Efficacy and safety of intra-class switching from Ixekizumab to Secukinumab in patients with plaque psoriasis. A multicenter retrospective study

Background: the present multicenter retrospective study aimed to evaluate the efficacy and safety of intra-class switching between interleukin-17A (IL-17A) inhibitors, specifically from ixekizumab to secukinumab, in patients with plaque psoriasis. Methods: this study included 11 patients (6 male, 5 female) who had previously received ixekizumab and then were switched to secukinumab. Patients’ PASI, DLQI, and pain VAS (in those with psoriatic arthritis) were evaluated at weeks 16, 24, 54, and 98. Results: PASI-90 was reached in 10 (91%) cases at week 24. One patient experienced secondary failure to secukinumab at week 98. No adverse events were reported. Conclusions: overall, the majority of patients experienced a favorable response to secukinumab, suggesting that it may be an effective treatment option for patients with an inadequate response or loss of efficacy to ixekizumab.